Table 2.

Participants with CD4⁺ T cell Rsps to 6 melanoma helper peptides vaccine

	High durable T cell Rsp in PBMC		Durable T cell Rsp in PBMC		Rsp in PBMC		hRsp in PBMC		Rsp in SIN	Rsp in PBMC by week 13 or in SIN
	#/n (%)	(90% CI)**	#/n (%)	(90% CI)**	#/n (%)	(90% CI)**	#/n (%)	(90% CI)**	#/n (%)	#/n (%)
PD-1 Ab naïve	1/6 (17%)	(1 to 58)	1/6 (17%)	(1 to 58)	4/6 (67%)	(27 to 94)	3/6 (50%)	(15 to 85)	0/3 (0%)	4/6 (67%)
PD-1 Ab experienced	0/16 (0%)	(0 to 17)	1/16 (6%)	(0 to 26)	2/16 (12.5%)	(2 to 34)	2/16 (12.5%)	(2 to 34)	1/7 (14%)†	3/16 (19%)
All participants	1/22 (4.5%)	(0 to 20)	2/22 (9%)	(2 to 26)	6/22 (27%)	(13 to 47)	5/22 (23%)	(9 to 42)	1/10 (10%)†	7/22 (32%)

*The Clopper-Pearson exact method was used to generate 90% CIs.

†This participant met criteria for both Rsp and hRsp in the SIN.

Ab, antibody; hRsp, high T cell response; PBMC, peripheral-blood mononuclear cell; PD-1, programmed cell death protein 1; Rsp, any T cell response; SIN, sentinel immunized node.